Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral Phenotype: A positron emission tomography study with 11C-(+)-PHNO

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 311-318

  Payer, Doris E ^a   Behzadi, Arian ^a   Kish, Stephen J ^a,b   Houle, Sylvain ^a,b,c   Wilson, Alan A ^a   Rusjan, Pablo M ^a   Tong, Junchao ^a   Selby, Peter ^a,c   George, Tony P ^a   McCluskey, Tina ^a   Boileau, Isabelle ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

11 C raclopride; 11C (+) PHNO; cocaine dependence; D2 3dopamine receptor; impulsiveness; risky decision making

Indexed keywords

BIOLOGICAL MARKER; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE C 11; RACLOPRIDE C 11; TRACER; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; IMPULSIVENESS; MALE; MASK; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHENOTYPE; POSITRON CAMERA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; ADDICTION; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; BEHAVIOR, ADDICTIVE; CARBON RADIOISOTOPES; COCAINE-RELATED DISORDERS; DOPAMINE ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D3;

EID: 84890552177     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.192     Document Type: Article

References (50)

1. Beck AT, Steer RA (1984). Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 40: 1365-1367.
2. Bohn MJ, Krahn DD, Staehler BA (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606.
3. Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM et al (2012a). The D(2/3) dopamine receptor in pathological gambling: a positron emission tomography study with [(11) C]-(\+) propyl-hexahydro-naphtho-oxazin and [(11) C]raclopride. Addiction (Abingdon, England) 108: 953-963.
4. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J et al (2012b). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(\+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353-1359.
5. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997). Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94: 3363-3367.
6. Brand M, Kalbe E, Labudda K, Fujiwara E, Kessler J, Markowitsch HJ (2005). Decision-making impairments in patients with pathological gambling. Psychiatry Res 133: 91-99.
7. Cole DM, Beckmann CF, Searle GE, Plisson C, Tziortzi AC Nichols TE et al (2012). Orbitofrontal connectivity with restingstate networks is associated with midbrain dopamine D3 receptor availability. Cereb Cortex 22: 2784-2793.
8. Conners CK (1994). The Continuous Performance Test (CPT): Use as a Diagnostic Tool and Measure of Treatment Outcome Los Angeles
9. CA. Davila V, Yan Z, Craciun LC, Logothetis D, Sulzer D (2003). D3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons. J Neurosci 23: 5693-5697.
10. Degenhardt L, Hall W (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379: 55-70.
11. D'Sa C, Fox HC, Hong AK, Dileone RJ, Sinha R (2011). Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biol Psychiatry 70: 706-711.
12. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S et al (2007). Positron emission tomography quantification of [11C]-(\+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27: 857-871.
13. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R Rusjan P et al (2008). Brain region binding of the D2/3 agonist [11C]-(\+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29: 400-410.
14. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001). BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411: 86-89.
15. Haile CN, Mahoney JJ, Newton TF, De La Garza R II (2012). Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther 134: 260-277.
16. Heidbreder CA, Gardner EL, Xi Z-X, Thanos PK, Mugnaini M Hagan JJ et al (2005). The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49: 77-105.
17. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 1187: 4-34.
18. James D, Davies G, Willner P (2004). The development and initial validation of a questionnaire to measure craving for amphetamine. Addiction (Abingdon, England) 99: 1181-1188.
19. Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI Weinrieb RM, D'Angelo L et al (1998). Reliability and validity of the cocaine selective severity assessment. Addict Behav 23: 449-461.
20. Kirby KN (2000). Instructions for Inferring Discount Rates from Choices between Immediate and Delayed Rewards.
21. Willamstown MA. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4: 153-158.
22. LeFoll B, Goldberg SR, Sokoloff P (2005). The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49: 525-541.
23. LeFoll B, Goldberg SR, Sokoloff P (2007). Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert opinion on investigational drugs 16: 45-57.
24. Lejuez CW, Read JP, Kahler CW, Richards JB, Ramsey SE, Stuart GL et al (2002). Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART). J Exp Psychol Appl 8: 75-84.
25. Martinez D, Broft A, Foltin RW, Slifstein M, Hwang D-R, Huang Y et al (2004). Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 29: 1190-1202.
26. Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC et al (2011). Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry 168: 634-641.
27. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang D-R, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
28. Matuskey D, Gallezot J-D, Lim K, Zheng M-Q, Lin S, Carson RE et al (2011). Subcortical D3/D2 receptor binding in cocaine dependent humans. J Nuclear Med (Meeting Abstracts) 52(Supl): 1284.
29. Melis M, Spiga S, Diana M (2005). The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 63: 101-154.
30. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C et al (2013). Occupancy of brain dopamine d(3) receptors and drug craving: a translational approach. Neuropsychopharmacology 38: 302-312.
31. Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994). Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91: 11271-11275.
32. Narendran R, Martinez D, Mason NS, Lopresti BJ, Himes ML, Chen C-M et al (2011). Imaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C]NPA positron emission tomography study. Synapse (New York, NY) 65: 1344-1349.
33. Nathan PJ, O'Neill BV, Mogg K, Bradley BP, Beaver J, Bani M et al (2012). The effects of the dopamine D receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Inter J Neuropsychopharmacol 15: 149-161.
34. Patton JH, Stanford MS, Barratt ES (1995). Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51: 768-774.
35. Rabiner EA, Laruelle M (2010). Imaging the D3 receptor in humans in vivo using [11C](\+)-PHNO positron emission tomography (PET). Inter J Neuropsychopharmacol 13: 289-290.
36. Reitan RM (1955). The relation of the trail making test to organic brain damage. J Consult Psychol 19: 393-394.
37. Richtand NM, Woods SC, Berger SP, Strakowski SM (2001). D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25: 427-443.
38. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79-89.
39. Seeman P, McCormick PN, Kapur S (2007). Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](\+)PHNO. Synapse (New York, NY) 61: 263-267.
40. Segal DM, Moraes CT, Mash DC (1997). Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 45: 335-339.
41. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, Aart J, van der Abanades S et al (2012). Within-subject comparison of [(11)C] (\+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cerebral Blood Flow Metab 32: 127-136.
42. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D Trigwell P (1995). A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 167: 99-103.
43. Sokoloff P, Foll B, Le, Perachon S, Bordet R, Ridray S, Schwartz JC (2001). The dopamine D3 receptor and drug addiction. Neurotoxicity Res 3: 433-441.
44. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
45. Staley JK, Mash DC (1996). Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16: 6100-6106.
46. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD Jenkinson M et al (2011). Imaging dopamine receptors in humans with [11C]-(\+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 54: 264-277.
47. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al (2012). Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17: 918-925.
48. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S et al (2008). First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(\+)-PHNO positron emission tomography study. Neuropsychopharmacology 33: 279-289.
49. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P et al (2006). High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(\+)-PHNO. Biol Psychiatry 59: 389-394.
50. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(\+)-4 propyl-3,4,4a,5,6,10b- hexahydro-2H-naphtho[1,2-b][1,4]oxazin 9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.